Clinical management of acute hepatic failure

Intensive Care Medicine

Volumn 27, Issue 3, 2001, Pages 467-476

  Rahman, Tony ^a   Hodgson, Humphrey ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bioartificial; Cerebral; Hepatic failure; Hepatorenal; Liver failure; Transplantation

Indexed keywords

ARTICLE; BLOOD CLOTTING DISORDER; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; KIDNEY DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; MORTALITY; MULTIPLE ORGAN FAILURE; PATIENT CARE; PRACTICE GUIDELINE;

BRAIN EDEMA; DISEASE PROGRESSION; HUMANS; INFECTION; INTENSIVE CARE; KIDNEY FAILURE; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; LIVER, ARTIFICIAL; MONITORING, PHYSIOLOGIC; MULTIPLE ORGAN FAILURE; PATIENT SELECTION; PRACTICE GUIDELINES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0035094345     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340100873     Document Type: Article

References (76)

1. Halothane and liver damage
2. Acute liver failure: Redefining the syndromes
3. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993)
4. Anti-tuberculous therapy and acute liver failure
5. Viral hepatitis and pregnancy
6. Pregnancy and liver disease
7. Mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications
8. Fulminant hepatic failure
9. Deaths from low dose paracetamol poisoning
10. Acute liver failure; clinical features and management
11. Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis
12. Selective increases of extracellular brain concentrations of aromatic and branched-chain amino acids in relation to deterioration of neurological status in acute (ischemic) liver failure
13. Hepatic encephalopathy: Molecular mechanisms underlying the clinical syndrome
14. Paracetamol hepatotoxicity
15. Pathophysiological changes in cerebral circulation, oxidative metabolism and blood-brain barrier in patients with acute liver failure - Tailored cerebral oxygen utilization
16. Indomethacin normalizes intracranial pressure in acute liver failure: A twenty-three-year-old woman treated with indomethacin
17. Cerebral blood flow and metabolism in fulminant liver failure
18. Changes in intracranial pressure during haemofiltration in oliguric patients with grade IV hepatic encephalopathy
19. Cerebral edema and intracranial pressure monitoring
20. Continuous monitoring of cerebrospinal fluid acid-base balance and oxygen metabolism in patients with severe head injury: Pathophysiology and treatments for cerebral acidosis and ischemia
21. Brain water and acute liver failure: The emerging role of intracranial pressure monitoring
22. Recovery despite impaired cerebral perfusion in fulminant hepatic failure
23. Circulatory, respiratory, cerebral and renal derangements in acute liver failure: Pathophysiology and management
24. Osmotherapy for elevated intracranial pressure: A critical reappraisal
25. Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure
26. Liver function, cerebral blood flow autoregulation, and hepatic encephalopathy in fulminant hepatic failure
27. Hyperventilation restores cerebral blood flow autoregulation in patients with acute liver failure
28. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure
29. Continuous venovenous hemofiltration with dialysis in combination with total hepatectomy and portocaval shunting. Bridge to liver transplantation
30. Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: Relation to other prognostic indicators
31. Omeprazole in the management of intractable esophageal ulceration following injection sclerotherapy
32. A comparison of direct and indirect measurements of oxygen delivery and consumption: The effects of prostacyclin in two human volunteers
33. The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients
34. Western blot analysis of bile or intestinal fluid from patients with septic shock or systemic inflammatory response syndrome, using antibodies to TNF-alpha, IL-1 alpha and IL-1 beta
35. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: A prospective controlled trial
36. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure
37. The effect of N-acetylcysteine on oxygen transport and uptake in patients with fulminant hepatic failure
38. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis
39. Serum sodium is inversely proportional to intracranial pressure in acute liver failure
40. Comparison of cardiac output assessed by pulse contour analysis and thermodilution in patients undergoing minimally invasive direct coronary artery bypass grafting
41. 2 exchange and energy balance
42. Goal-directed therapy with dopexamine, dobutamine, and volume expansion: Effects of systemic oxygen transport on hepatic ultrastructure in porcine sepsis
43. Dopexamine maintains portal blood flow and attenuates hepatic ultrastructural changes in a porcine peritonitis model of multiple system organ failure
44. Dopexamine: Much more than a vasoactive agent
45. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome
46. Hepatorenal syndrome: Definition, pathophysiology, clinical features and management
47. Renal-dose (low-dose) dopamine for the treatment of sepsis-related and other forms of acute renal failure: Ineffective and probably dangerous
48. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects
49. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome
50. Loop diuretics in the management of acute renal failure: A prospective, double-blind, placebo-controlled, randomized study
51. Management of patients with renal failure complicated by cerebral oedema
52. Preliminary experience with high-volume hemofiltration in human septic shock
53. High-volume continuous venous-venous haemofiltration in hyper-acute liver failure: A pilot study
54. Microbiologic findings and correlations with serum tumor necrosis factor-alpha in patients with severe sepsis and septic shock
55. Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant liver failure
56. Fungal infection: A common, unrecognised complication of acute liver failure
57. Immunonutrition in the critically ill: A systematic review of clinical outcome
58. Homotransplantation of the liver in humans
59. Liver transplantation
60. The UNOS OPTN waiting list and donor registry
61. Early indicators of prognosis in fulminant hepatic failure
62. Early indicators of prognosis in fulminant hepatic failure: An assessment of the King's criteria
63. Split liver transplantation: A way forward?
64. Auxiliary partial orthotopic liver transplantation (APOLT) for fulminant hepatic failure: First successful case report
65. Auxiliary fiver transplantation: Regeneration of the native liver and outcome in 30 patients with fulminant hepatic failure - A multicenter European study
66. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver
67. High volume plasma exchange in fulminant hepatic failure
68. Development of a bioartificial liver: Properties and function of a hollow-fiber module inoculated with liver cells
69. Reversal of fulminant hepatic failure using an extracorporeal liver assist device
70. Hepatocellular transplantation (HCT) in children with fulminant liver failure (FLF)
71. Percutaneous hepatocyte transplantation (PHT) in liver failure
72. Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure
73. Clinical experience with a porcine hepatocyte-based liver support system
74. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial
75. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure